arrow
D

Darell D. Bigner

Duke University
H指数:147
被引数:15.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

INVESTIGATION OF THE COMBINATION OF D2C7-IT WITH AN FC-ENGINEERED ANTI-HUMANCD40 MONOCLONAL ANTIBODY (2141-V11) WHEN ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOLLOWED BY CERVICAL PERILYMPHATIC INJECTIONS (CPLIS) OF 2141-V11 COMPARED TO D2C7-IT CED MONOTHERAPY IN PATIENTS WITH RECURRENT GLIOBLASTOMA (RGBM)

探究通过促进增强递送(CED)途径瘤内给药D2C7-IT与FC工程化抗人CD40单克隆抗体(2141-V11)联合应用,并随后进行2141-V11颈部淋巴周围注射(CPLIS)与D2C7-IT CED单药治疗相比,在复发性胶质母细胞瘤(RGBM)患者中的效果。

2025-11-010
OAAI
An assessment of the Tumor Monorail Device (TMD) for repeated sampling as part of a trial evaluating the combination of D2C7-IT and an Fc-engineered anti-CD40 monoclonal antibody (2141-V11) administered intratumorally via convection-enhanced delivery (CED) and cervical perilymphatic injections (CPLIs) of 2141-V11 in recurrent glioblastoma (rGBM) patients

对Tumor Monorail Device (TMD)进行重复采样的评估,作为一项评估通过对流增强递送(CED)和颈周淋巴间隙注射(CPLIs)分别经瘤内给予D2C7-IT以及Fc工程化抗CD40单克隆抗体(2141-V11)的联合方案在复发性胶质母细胞瘤(rGBM)患者中疗效试验的一部分。

2025-11-010
OAAI
Randomized phase 2 clinical trial of repeated intratumoral and cervical perilymphatic injections (CPLIs) of lerapolturev vs. lomustine in recurrent glioblastoma (rGBM): safety lead-in results

lerapolturev与洛莫司汀在复发性胶质母细胞瘤(rGBM)中的随机化Ⅱ期临床试验:重复肿瘤内和颈部淋巴周围注射(CPLIs)的安全导引入组结果

2025-11-010
OAAI
D2C7-IT IN COMBINATION WITH AN FC-ENGINEERED ANTI-HUMANCD40 MONOCLONAL ANTIBODY (2141-V11) ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOLLOWED BY CERVICAL PERILYMPHATIC INJECTIONS (CPLIS) OF 2141-V11 IN PATIENTS WITH RECURRENT GLIOBLASTOMA (RGBM)
2024-11-110
PRE
Recombinant polio-rhinovirus immunotherapy for recurrent paediatric high-grade glioma: a phase 1b trial
2023-07-0116
OAAI
Immunotoxin-αCD40 therapy activates innate and adaptive immunity and generates a durable antitumor response in glioblastoma models
2023-02-0810
OA
Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy
2021-01-1393
OAAI
MTAP Loss Promotes Stemness in Glioblastoma and Confers Unique Susceptibility to Purine Starvation
2019-07-0130
OAAI